2015 COS Research Conference Keynote Speaker
Novel Therapeutical Approaches for Parkinson's Disease and Synucleinopathies of the Aging Population
by Eliezer Masliah, M.D.
Eliezer Masliah, M.D.
Dr. Masliah received his MD from the National Autonomous University of Mexico in 1982 and obtained his specialty in Pathology at the National Institutes of Health in Mexico City in 1986. From 1987-1989 he performed postdoctoral studies in Neuropathology and Neurodegeneration at the University of California, San Diego (UCSD), where he is currently a Tenured Professor, Director of the Laboratory of Experimental Neuropathology, and Director of the Autopsy Service at the UCSD-Medical Center. He has published over 600 original research articles, 60 books chapters, over 10 patents, and 4 programs initiated in his laboratory have now advanced to Phase I clinical trials.
Research in the Masliah Laboratory is dedicated to investigating the molecular mechanisms of synaptic degeneration and developing new therapies for neurological disorders such as Alzheimer’s Disease, Parkinson’s Disease, Multiple System Atrophy, HIV dementia, and other neurodegenerative disorders. His lab has developed transgenic mouse models of these neurodegenerative disorders and is actively involved in better understanding the mechanisms of synaptic damage and at developing novel treatments for these devastating disorders including gene therapy, immunotherapy, and small molecule approaches to reduce protein misfolding and aggregation.
His laboratory has developed new brain penetrating gene therapy and immunotherapy approaches directed at reducing the accumulation of Abeta, Tau, and α-synuclein that hold the promise of helping to develop new therapies that will enhance the clearance and reduce the synaptic pathology in neurodegenerative disorders.